I asked if I could purchase the brace myself and bring it to the surgery. The answer was an unequivocal no: the health insurer’s contracted rate required me to purchase the brace from the hospital as part of the procedure. The post A 2,100% Markup: My Battle with a Vastly Overpriced Knee Brace — and…
SHREVEPORT, La. — When Robert Smith met his future girlfriend in 2010, he wanted to take things slowly. For Smith, no relationship had been easy in the years since he was diagnosed with the human immunodeficiency virus, or HIV. People often became afraid when they learned his status, even running away when he coughed. The…
Medicare enrollees who buy the optional Part D drug benefit may see substantial premium price hikes — potentially up to $50 a month — when they shop for next year’s coverage. Such drug plans are used by millions of people who enroll in what is called original Medicare, the classic federal government program that began…
By aligning innovative scientific insights with strategic commercial pathways, the industry has the potential to fulfill its early promise – delivering safe, effective therapies that improve patient outcomes and create new opportunities for growth in the biopharmaceutical sector. The post Beyond the Hype: The Scientific and Commercial Future of Microbiome Medicine appeared first on MedCity…
Following a months-long dispute, data platform Particle Health filed an antitrust lawsuit against Epic, alleging that the EHR giant is using its dominance in the market to prevent competition in the payer platform space. Particle believes the lawsuit is an “unprecedented challenge” to Epic’s market power, while Epic thinks the startup’s claims are “baseless.” The…
Amperos Health’s Series A round was led by Bessemer Venture Partners, with participation from Uncork Capital and Neo. The post Startup Helping Providers Manage Denied Claims Raises $16M appeared first on MedCity News.
Recent changes to ACIP leadership and vaccine guidance have raised concerns that longstanding immunization protections are being weakened, potentially leading to lower vaccination rates and more preventable disease. The post ‘What Else Is Going to Change?’: What ACIP’s Hep B Guidance Means for the Future of Vaccines appeared first on MedCity News.
By JEFF GOLDSMITH A Forty Year Growth Saga is Coming to an End After market close Wednesday April 16, UnitedHealth Group reported its First Quarter 2025 earnings. UNH missed their expected 1Q earnings by 9 cents a share, but the firm also lowered its full year 2025 earnings estimate by 12%. On Thursday opening, investors…
Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…
Medicare officials are pushing back against a federal watchdog’s call to crack down on home visits by Medicare Advantage health plans — a practice the watchdog says may waste billions of tax dollars every year. In late October, a Health and Human Services inspector general audit found that the insurers pocketed $7.5 billion in 2023 from diagnosing health conditions that…